Novo Nordisk A/S (NONOF)
38.93
+0.03
(+0.07%)
USD |
OTCM |
Oct 26, 16:00
Novo Nordisk Enterprise Value : 186.64B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 186.64B |
| October 23, 2026 | 186.52B |
| October 22, 2026 | 188.90B |
| October 21, 2026 | 186.52B |
| October 20, 2026 | 186.81B |
| October 19, 2026 | 183.62B |
| October 16, 2026 | 186.25B |
| October 15, 2026 | 189.06B |
| October 14, 2026 | 181.17B |
| October 13, 2026 | 182.34B |
| October 12, 2026 | 186.03B |
| October 09, 2026 | 183.20B |
| October 08, 2026 | 183.78B |
| October 07, 2026 | 181.62B |
| October 06, 2026 | 179.86B |
| October 05, 2026 | 179.61B |
| October 02, 2026 | 178.16B |
| October 01, 2026 | 179.79B |
| September 30, 2026 | 183.20B |
| September 29, 2026 | 184.06B |
| September 28, 2026 | 184.22B |
| September 25, 2026 | 185.44B |
| September 24, 2026 | 184.31B |
| September 23, 2026 | 183.65B |
| September 22, 2026 | 188.38B |
| Date | Value |
|---|---|
| September 21, 2026 | 191.03B |
| September 18, 2026 | 202.95B |
| September 17, 2026 | 200.21B |
| September 16, 2026 | 198.27B |
| September 15, 2026 | 202.06B |
| September 14, 2026 | 207.60B |
| September 11, 2026 | 205.48B |
| September 10, 2026 | 209.70B |
| September 09, 2026 | 211.14B |
| September 08, 2026 | 215.44B |
| September 04, 2026 | 219.26B |
| September 03, 2026 | 220.12B |
| September 02, 2026 | 221.66B |
| September 01, 2026 | 215.03B |
| August 31, 2026 | 214.58B |
| August 28, 2026 | 213.56B |
| August 27, 2026 | 218.59B |
| August 26, 2026 | 224.05B |
| August 25, 2026 | 227.30B |
| August 24, 2026 | 222.33B |
| August 21, 2026 | 221.49B |
| August 20, 2026 | 219.37B |
| August 19, 2026 | 215.27B |
| August 18, 2026 | 213.12B |
| August 17, 2026 | 213.97B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.250T |
| ALK-Abello A/S | 7.898B |
| H. Lundbeck A/S | 7.901B |
| AstraZeneca PLC | 559.97B |
| GSK Plc | 122.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.265B |
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| EPS Diluted (Quarterly) | 0.7362 |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 10.51% |
| Operating Earnings Yield | 13.49% |
| Normalized Earnings Yield | 10.94 |